ID   NB4R
AC   CVCL_IY15
DR   cancercelllines; CVCL_IY15
DR   Wikidata; Q54907540
RX   Patent=US5589345;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:15367; All-trans-retinoic acid (ATRA; Tretinoin).
CC   Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala18Asp (c.53C>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C3182; Acute promyelocytic leukemia with PML-RARA
DI   ORDO; Orphanet_520; Acute promyelocytic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0005 ! NB4
SX   Female
AG   23Y
CA   Cancer cell line
DT   Created: 15-05-17; Last updated: 05-10-23; Version: 14
//
RX   Patent=US5589345;
RA   Lanotte M., Berger R.;
RT   "Cultures of permanent lines of human promyelocytic cells and their
RT   uses for the screening of molecules utilizable in particular in the
RT   treatment of leukemias.";
RL   Patent number US5589345, 31-Dec-1996.
//